The emergence of biologics with different modes of action (MoAs) and therapeutic targets
has changed treatment patterns in patients with inflammatory rheumatic diseases. While …

Objectives Previous studies demonstrated equivalence in terms of efficacy and safety of
biosimilars (bsDMARDs) compared to original treatments (boDMARDs) and in switching …

Objectives Adults with RA are being switched from etanercept originator to biosimilar in non-
medical/cost-saving switching. This analysis aims to investigate outcomes in these patients …

Introduction SB4 is the first approved biosimilar of etanercept, a biologic tumor necrosis
factor inhibitor, to treat various autoimmune diseases including axial spondylarthritis …

Objective To improve knowledge about biosimilar medicines and to generate a consensus
framework on their use. Methods Qualitative study. A multidisciplinary group of experts in …

Introduction To better inform clinicians about the use of etanercept biosimilar (SB4) in
patients with rheumatoid arthritis (RA), COMPANION-B, a prospective real-world …

Purpose: To investigate the disease activity in real-world patients with rheumatoid arthritis
(RA) who switched from originator etanercept (ETN) to biosimilar YLB113. Methods: Forty …

Objetivo Mejorar el nivel de conocimiento sobre los medicamentos biosimilares y generar
un marco consensuado sobre su uso. Métodos Estudio cualitativo. Se seleccionó un grupo …

There was an overall feeling at the EORTC-CLTG meeting that further research is needed to
better define the molecular basis for the different forms of cutaneous T cell lymphoma …

Background: Previous experiences with non-medical switching of adalimumab (ADA) in
patients with chronic inflammatory rheumatic diseases (CIRD) come mainly from phase III …